Guselkumab vs Golimumab for Psoriatic Arthritis
(EVOLUTION Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Will I have to stop taking my current medications?
The trial requires that you stay on a stable dose of any oral small molecule drugs, NSAIDs, glucocorticoids (less than 10 mg daily), or topical medications for psoriasis that you are currently using. You must have been on this stable dose for at least 4 weeks before starting the trial and continue it during the study.
Is Guselkumab or Golimumab safe for humans?
How does the drug Guselkumab differ from other treatments for psoriatic arthritis?
What data supports the effectiveness of the drugs Guselkumab and Golimumab for treating psoriatic arthritis?
Research shows that Golimumab is effective for psoriatic arthritis, especially for patients who did not respond to other similar treatments. Guselkumab has also shown positive results in improving symptoms in psoriatic arthritis and has been effective in treating plaque psoriasis, which is related to psoriatic arthritis.59111213
Who Is on the Research Team?
Alexis Ogdie-Beatty, MD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for adults aged 18-80 with active psoriatic arthritis who have not responded well to TNF inhibitors. Participants must have at least one active psoriasis plaque and meet specific criteria for joint swelling or tenderness. They should be on a stable dose of certain medications if used, but cannot be pregnant, trying to conceive, or have had serious reactions to similar drugs.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either guselkumab or golimumab based on randomization to assess effectiveness in PsA patients with inadequate response to TNFi
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Golimumab
- Guselkumab
- Placebo
Golimumab is already approved in European Union, United States, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Janssen Scientific Affairs, LLC
Industry Sponsor
Joaquin Duato
Janssen Scientific Affairs, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Scientific Affairs, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University